1. Code of Federal Regulations (CFR), Title 21 CFR Part 312.305. US Food & Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.305. Updated April 1, 2017. Accessed September 13, 2017.
2. Investigational new drugs: FDA has taken steps to improve the expanded access program but should further clarify how adverse events data are used. US Government Accountability Office. https://www.gao.gov/products/GAO-17-564. Published July 11, 2017. Accessed November 10, 2017.
3. Expanded access to investigational drugs for treatment use—questions and answers, guidance for industry. Food and Drug Administration. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm351261.pdf. Published June 2016. Updated October 2017. Accessed September 15, 2017.
4. Gottlieb S. Expanded access: FDA describes efforts to ease application process. FDA Voice. https://blogs.fda.gov/fdavoice/index.php/2017/10/expanded-access-fda-describes-efforts-to-ease-application-process/. Published October 3, 2017. Accessed November 10, 2017.
5. Jarow JP, Lemery S, Bugin K. Expanded access of investigational drugs: the experience of the center of drug evaluation and research over a 10-year period. Therapeutic Innovation & Regulatory Science. 2016;50:705–709.